Concepedia

Author

Sarah Scagliarini

Istituti di Ricovero e Cura a Carattere ScientificoORCID

Also Known As

Andrea Sbrana, Riccardo Santoni, S Scagliarini, S. SCAGLIARINI, S. Scagliarini, SARAH SCAGLIARINI, Sarah SCAGLIARINI, Sarah Scagliarini

91

Publications

778

Citations

15

H-Index

14

Concepts

All Affiliations

Istituti di Ricovero e Cura a Carattere ScientificoIstituto Oncologico VenetoUniversity of ParmaIstituto Scientifico Romagnolo per lo Studio e la Cura dei TumoriFondazione IRCCS Istituto Nazionale dei Tumori
SS

About

Sarah Scagliarini is an author at Istituti di Ricovero e Cura a Carattere Scientifico specializing in medicine, urology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

8

8

211

2

Pharmacology

2

2

54

3

Cancer Therapeutics

2

2

33

4

Health Sciences

1

1

21

5

Pathology

1

1

26

Sarah Scagliarini

×

17

Publications

421

Citations

13

H-Index

YearCitations

Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?

Matteo Santoni, Sebastiano Buti, Zin Myint,

European Urology Oncology

2023

52

A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)

Giuseppe Procopio, Mélanie Claps, Chiara Pircher,

Tumori Journal

2022

46

Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study

Matteo Santoni, Francesco Massari, Zin Myint,

Targeted Oncology

2023

34

Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors

Matteo Santoni, Daniel Y.C. Heng, Sergio Bracarda,

Cancers

2019

31

Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or Later Line) Systemic Treatment: A Retrospective, Multi-Center Study

Carlo Buonerba, Giuseppe Di Lorenzo, Gregory R. Pond,

Frontiers in Pharmacology

2016

28

Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate

Giuseppe Di Lorenzo, Guru Sonpavde, Gregory R. Pond,

European Urology Focus

2017

28

Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)

Matteo Santoni, Francesco Massari, Zin Myint,

Clinical Genitourinary Cancer

2023

26

Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study

Ondřej Fiala, Sebastiano Buti, Hideki Takeshita,

Cancer Immunology Immunotherapy

2023

26

Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy

Maria Giuseppa Vitale, Sarah Scagliarini, Luca Galli,

PLoS ONE

2018

24

Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma

Michele Prisciandaro, Raffaele Ratta, Francesco Massari,

American Journal of Clinical Oncology

2018

24

Page 1